TY  - JOUR
AU  - Zaghla, Badeel Kh Q
AU  - Safyürek, Zuhal
AU  - Gröger, Daniela
AU  - Mecklenbräuker, Shima
AU  - Lingstädt, Nina-Sophie
AU  - Popp, Oliver
AU  - Spengler, Johanna
AU  - Haji, Mohamed
AU  - Montesion, Meagan
AU  - Albacker, Lee A
AU  - Mertins, Philipp
AU  - Klatt, Martin Gunther
TI  - Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 14
IS  - 1
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2026-00071
SP  - e013271
PY  - 2026
N1  - #DKTKZFB26#
AB  - Peptide presentation on human leukocyte antigens (HLAs) is essential for initiating T-cell responses and all consequences of this presentation including anticancer immunity or immune escape. Many studies have relied on in silico prediction tools rather than biological measurement of HLA presentation to study these effects. To better assess the frequency and consequences of neoantigen presentation, we overexpressed 125 combinations of full-length neoantigens and one HLA class I allele to experimentally validate presentation of mutated and non-mutated HLA ligands through HLA ligand isolation followed by tandem mass spectrometry. A successful presentation was observed only in 22
KW  - Humans
KW  - Immune Evasion
KW  - T-Lymphocytes: immunology
KW  - Epitopes, T-Lymphocyte: immunology
KW  - Antigens, Neoplasm: immunology
KW  - Antigens, Neoplasm: genetics
KW  - Antigen Presentation: immunology
KW  - HLA Antigens: immunology
KW  - HLA Antigens: genetics
KW  - Cancer Vaccines: immunology
KW  - Histocompatibility Antigens Class I: immunology
KW  - Histocompatibility Antigens Class I: genetics
KW  - Human leukocyte antigen - HLA (Other)
KW  - Immunotherapy (Other)
KW  - T cell Receptor - TCR (Other)
KW  - Vaccine (Other)
KW  - Epitopes, T-Lymphocyte (NLM Chemicals)
KW  - Antigens, Neoplasm (NLM Chemicals)
KW  - HLA Antigens (NLM Chemicals)
KW  - Cancer Vaccines (NLM Chemicals)
KW  - Histocompatibility Antigens Class I (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41506790
DO  - DOI:10.1136/jitc-2025-013271
UR  - https://inrepo02.dkfz.de/record/307576
ER  -